Isto Technologies

About Isto Technologies

Isto Biologics operates as a specialized orthobiologics company, focusing on evidence-based solutions for bone regeneration and cell therapy aimed at improving patient outcomes. The company's genesis dates back to October 2016, through the strategic integration of St. Louis-based Isto Technologies and Hopkinton, Massachusetts-based Arteriocyte Medical Systems Inc. This merger was financially backed by Thompson Street Capital Partners, a private equity firm. The company is currently led by CEO Don Brown.

The formation of Isto Biologics created a more extensive product portfolio and a broader distribution network, enhancing its reach within the spine, orthopedics, and functional medicine markets. Arteriocyte, formed in 2004 as a spinout from a collaboration including Case Western Reserve University and the Cleveland Clinic Foundation, brought its market-leading Magellan® Autologous Platelet Separator to the table. Isto Technologies, founded in 1997, contributed its expertise in bone-growth and cell-therapy products. The company has continued to grow through acquisitions, including Progenicare in 2017, TheraCell, Inc. in 2022, and a merger with Advanced Biologics in 2023.

Isto Biologics' business model is centered on providing surgeons and healthcare facilities with advanced biologic and cell-based therapies. Its revenue is generated through the sale of its product lines to clients in the orthopedic, spine surgery, and sports medicine sectors. The company's product offerings are categorized into autologous therapies, allografts, and synthetics. Key products include the Magellan® Autologous Platelet Separator, an automated system for preparing platelet-rich plasma (PRP) and other concentrations from a patient's own blood at the point of care. The InQu® line is a biosynthetic bone graft substitute that combines a resorbable polymer with hyaluronic acid to create a scaffold for bone regeneration, used to fill bony voids and extend autografts. The Influx™ family consists of allografts, which are 100% human bone grafts—including cortical fibers and demineralized bone matrix (DBM)—designed to provide a scaffold for new bone growth without fillers.